Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Liposome Encapsulated Docetaxel (LE-DT) is a novel proprietary delivery system of docetaxel
developed by NeoPharm, Inc. In this Phase I study, the LE-DT was evaluated for the maximum
tolerated dose and dose limiting toxicity (DLT) in patients with advance solid tumors. It was
also evaluated for pharmacokinetic and anti-tumor effects.